NPCE earnings analysis
What we found in NPCE's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NeuroPace delivered $22.826 million of Q2 revenue and a $0.18 diluted loss, beating consensus and improving EPS sequentially and year over year. Core RNS revenue remained strong at $22.5 million, up 21.3%, but total revenue was below the prior-year quarter and the company continues to consume cash while reporting substantial cumulative losses. Liquidity, secured debt covenants, the constrained current FDA indication, and execution risks around FDA expansion and manufacturing remain material offsets to the improving loss profile.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue beat estimates sequentially
- Revenue was $22.826 million, approximately 0.7% above the $22.662 million consensus estimate. Revenue increased about 3.8% from $22 million in 2026 Q1 but declined about 4.9% from $24 million in 2025 Q2.
- Loss narrowed sequentially and year over year
- Diluted EPS was a loss of $0.18 versus the $0.19 consensus loss, a $0.01 beat. EPS improved from a $0.20 loss in 2026 Q1 and a $0.26 loss in 2025 Q2.
- Core RNS growth remained strong
- Core RNS System revenue reached $22.5 million, representing 21.3% year-over-year growth and approximately 98.6% of total quarterly revenue of $22.826 million.
- Year-to-date net loss improved
- For the six months ended June 30, 2026, net loss was $12.9 million versus $15.2 million in the prior-year period, an improvement of $2.3 million or approximately 15.1%.
- Liquidity exceeds current liabilities
- Management reported $51.7 million of cash, cash equivalents and short-term investments at June 30, 2026, providing liquidity against $17.4 million of current liabilities.
- No reported control deficiencies
- Disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, and the company reported no material changes to internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity runway remains a key risk
- Cash, cash equivalents and short-term investments declined to $51.7 million from $61.1 million at December 31, 2025. Net cash used in operating activities was $9.8 million for the six months ended June 30, 2026, versus $9.6 million in the prior-year period.
- Persistent losses and funding needs
- The company reported a six-month net loss of $12.9 million and an accumulated deficit of approximately $565.3 million as of June 30, 2026, and stated that it expects to continue incurring losses for the foreseeable future.
- Debt covenants constrain flexibility
- The MidCap Term Loan includes a minimum liquidity covenant and a quarterly revenue covenant, is secured by substantially all company assets including intellectual property, and could become immediately due upon an uncured default.
- FDA delays threaten expansion plans
- The filing newly emphasizes FDA staffing changes and states that cuts and staffing changes could delay reviews of indication-expansion submissions for IGE and patients ages 12 to 17. The current RNS indication remains limited to adults with drug-resistant focal epilepsy in the United States.
- New QMSR and single-site exposure
- The filing states that the FDA’s QMSR superseded the prior QSR on February 2, 2026. Because the company manufactures the RNS System in one facility and relies on several single-source suppliers, compliance, yield or supply disruptions could interrupt production.
- AI, privacy and cybersecurity exposure
- The filing adds or expands risks related to AI/ML, including the FDA-approved ECoG Assistant, and states that EU GDPR penalties can reach €20 million or 4% of annual global revenue, whichever is greater.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.18
- Segment
- RNS System: $22.5 million of revenue, up 21.3% year over year
- Segment
- Other revenue: approximately $0.3 million, based on total revenue of $22.826 million less RNS revenue
What they said about what is next.
The 10-Q discusses guidance generally but does not provide quantitative revenue or EPS guidance in the provided filing text. The quantitative 2026 outlook was provided separately in the August 11, 2026 earnings release: revenue of $99.5 million-$101.5 million, non-GAAP gross margin of 82.0%-83.0%, and Adjusted EBITDA loss of $7.5 million-$8.5 million; guidance excludes IGE indication expansion.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- NeuroPace reported Q1 2026 revenue of $22.1 million, slightly exceeding analyst expectations of $21.6 million, with an EPS loss of $0.20, surpassing estimates of a $0.22 loss. The company's gross margin improved to…
- 10-K · March 3, 2026
- NeuroPace’s 2025 10‑K emphasizes continued commercial expansion of its RNS System (now implanted in over 8,000 patients as of December 31, 2025) and improving operational performance following a February 2025 equity…
- 10-K · March 4, 2025
- NeuroPace highlights durable, improving clinical efficacy and an expanding commercial opportunity: as of December 31, 2024 over 6,000 patients have received the RNS System, post‑approval data show median seizure…
- 10-K · March 5, 2024
- NeuroPace positions its RNS System as a differentiated, data-driven closed‑loop neuromodulation therapy and is pursuing commercial expansion after a 2023 PMA-S that the company says enables qualification of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NPCE makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever